<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388268</url>
  </required_header>
  <id_info>
    <org_study_id>201708055</org_study_id>
    <nct_id>NCT03388268</nct_id>
  </id_info>
  <brief_title>TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment</brief_title>
  <official_title>Double Blinded, Randomized Controlled Trial of Oral Vancomycin Versus Placebo in Hospitalized Patients With Diarrhea and Stool toXin NEGative But Nucleic Acid Amplification Test Positive for Toxigenic Clostridium Difficile (TOX NEG Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the risks and benefits of antibiotic treatment for&#xD;
      Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid&#xD;
      amplification test (NAAT) positive and enzyme immunoassay (EIA) negative for C. difficile.&#xD;
&#xD;
      Currently, healthcare facilities use a wide variety of tests and strategies for identifying&#xD;
      patients with CDI; both EIA and NAAT are widely used. There is no clear gold standard for&#xD;
      identifying CDI. At WUSM and BJH, patients are only treated for CDI if they have a positive&#xD;
      EIA. However, at many other healthcare facilities, the standard of care is to treat for CDI&#xD;
      if the patient is NAAT positive. Some patients who are NAAT-positive may not have true CDI;&#xD;
      while this treatment is standard of care at many facilities, the risk and benefits of&#xD;
      treating these patients for CDI is unknown.&#xD;
&#xD;
      We propose to perform a double blinded, randomized controlled non-inferiority trial of&#xD;
      antimicrobial of patients who are EIA negative, NAAT positive to determine the risks and&#xD;
      benefits of CDI treatment in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Purpose:&#xD;
&#xD;
      The purpose of this study is to determine the risks and benefits of antibiotic treatment for&#xD;
      Clostridium difficile infection (CDI) among patients whose stool samples are nucleic acid&#xD;
      amplification test (NAAT) positive and enzyme immunoassay (EIA) negative for C. difficile.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Clostridium difficile infection (CDI) is the most common cause of healthcare-associated&#xD;
      diarrhea. There is no gold standard diagnostic test for (CDI). Commercially available assays&#xD;
      detect C. difficile or its toxins in stool. Nucleic acid amplification tests (NAAT) are much&#xD;
      more sensitive than toxin enzyme immunoassays (EIA). However, clinical correlation is needed&#xD;
      to determine who has CDI. Most US clinical microbiology laboratories have adopted NAATs for&#xD;
      C. difficile under the presumption the enhanced analytical sensitivity was beneficial.&#xD;
      Although some patients with NAAT-positive/toxin-negative stool have CDI and a false-negative&#xD;
      toxin EIA, subsequent studies indicate most patients with NAAT-positive / toxin-negative&#xD;
      stool do not have CDI. Rather, they are asymptomatic C. difficile carriers who have diarrhea&#xD;
      for other reasons. Most of these studies also have limitations and considerable controversy&#xD;
      remains for whether NAATs or toxin EIAs should be used when CDI is suspected.&#xD;
&#xD;
      Treatment of asymptomatic C. difficile carriers is not beneficial, and may result in harm. At&#xD;
      hospitals that utilize NAATs, most patients with NAAT-positive / toxin-negative stool receive&#xD;
      treatment for CDI. The most common treatments for CDI, metronidazole and oral vancomycin, are&#xD;
      highly disruptive of the intestinal microbiome. These antimicrobials create selective&#xD;
      pressures that promote the acquisition and proliferation of antimicrobial resistance and&#xD;
      multidrug resistant organisms (MDRO), including public health threats such as MDRO&#xD;
      Enterobacteriaceae like carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum&#xD;
      beta-lactamase (ESBL) producing organisms, vancomycin-resistant Enterococcus (VRE), and the&#xD;
      latest emerging threat Candida auris. This leads to MDRO infections and MDRO spread to&#xD;
      others. Paradoxically, unnecessary treatment for CDI may increase risk for CDI once treatment&#xD;
      is stopped contributing to CDI-related adverse events and C. difficile spread to others.&#xD;
      Unnecessary CDI treatment potentially harms both that patient and other people. Whether the&#xD;
      benefit of treating patients with NAAT-positive/toxin-negative stool that are missed cases of&#xD;
      CDI outweighs the risk of treating patients with NAAT-positive/toxin-negative stool that are&#xD;
      asymptomatic C. difficile carriers remains unknown.&#xD;
&#xD;
      This study is a double-blinded randomized controlled trial of CDI treatment for patients with&#xD;
      NAAT-positive / toxin-negative stool. Such a trial is necessary to understand the&#xD;
      risk-benefit of treating these patients for CDI. Patients with NAAT-positive / toxin-negative&#xD;
      stool who consent to participate will be randomized to 10 days of oral vancomycin or placebo.&#xD;
      Stool and environmental specimens will be obtained at regular time points and interrogated&#xD;
      with culturomic and metagenomic methods. Patients will be followed until eight weeks after&#xD;
      discontinuation of study drug. These data and specimens will be used to determine the impact&#xD;
      of oral vancomycin versus placebo on the microbiome, C. difficile and MDRO colonization,&#xD;
      environmental contamination, duration of diarrhea, CDI-related adverse events, and death.&#xD;
&#xD;
      Specific aims and hypotheses:&#xD;
&#xD;
      Specific Aim 1: Determine if there are differences in microbiome disruption and acquisition /&#xD;
      persistence of C. difficile and other MDRO carriage in stool among patients with&#xD;
      NAAT-positive / toxin-negative stool who are randomized to a 10-day course of oral vancomycin&#xD;
      versus placebo.&#xD;
&#xD;
      Hypotheses: Study participants who receive oral vancomycin will have greater disruption of&#xD;
      the taxonomic and functional metabolic profiles of the fecal microbiome, increases in&#xD;
      antimicrobial resistance genes, acquire more MDRO, and will have greater persistence and&#xD;
      abundance of MDRO in stool compared to participants who receive placebo. Participants who&#xD;
      receive oral vancomycin will not have detectable C. difficile in stool after completion of&#xD;
      study drug, but will be more likely to have C. difficile in stool at week 8 after completion&#xD;
      of study drug compared to participants who receive placebo.&#xD;
&#xD;
      Specific Aim 2: Determine if there are differences in C. difficile and other MDRO&#xD;
      environmental contamination between treatment groups.&#xD;
&#xD;
      Hypothesis: Study participants who receive oral vancomycin will have less environmental C.&#xD;
      difficile contamination but more MDRO contamination compared to participants who receive&#xD;
      placebo while receiving study drug. After study drug is completed, those who receive oral&#xD;
      vancomycin will have more environmental contamination due to both C. difficile and other&#xD;
      MDROs.&#xD;
&#xD;
      Specific Aim 3: Determine if there are differences in CDI-related outcomes between groups.&#xD;
&#xD;
      Hypothesis: There will be no difference in time to resolution of diarrhea or CDI-related&#xD;
      outcomes between treatment groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded randomized controlled trial of CDI treatment with oral vancomycin vs. placebo</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Detectable C. Difficile</measure>
    <time_frame>Through 8 weeks after completion of study drug</time_frame>
    <description>Stool specimens will be examined via culture and metagenomic analyses for the presence of detectable C. difficile. Presence will be defined as presence of culturable C. difficile in stool any time after collection of enrollment stool samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detectable Environmental Contamination</measure>
    <time_frame>Through 8 weeks after completion of study drug</time_frame>
    <description>Swabs from participants' home and hospital environments will be examined via culture and metagenomic analyses for the presence and/or persistence of C. difficile and other multidrug resistant organisms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Diarrhea in Study Participants as Defined by Daily Symptoms and Questionnaire Using the Bristol Stool Chart</measure>
    <time_frame>Through 8 weeks after completion of study drug</time_frame>
    <description>Duration of diarrhea will be compared between groups. Duration of diarrhea will be assessed daily during study drug using a questionnaire and the Bristol Stool Chart. The Bristol Stool Chart measures stool consistency. Diarrhea will be defined as Bristol Stool Chart types 5-7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Other Multidrug Resistant Organisms in the Gut Microbiome of Study Participants</measure>
    <time_frame>Through 8 weeks after completion of the study drug</time_frame>
    <description>Stool specimens will be examined via culture and metagenomic analyses for the presence of multidrug resistant organisms before and after study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Oral vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125mg of oral vancomycin four times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo four times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Vancomycin</intervention_name>
    <description>Oral vancomycin 125mg 4 times per day</description>
    <arm_group_label>Oral vancomycin</arm_group_label>
    <other_name>Vancocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar liquid manufactured to mimic oral vancomycin 125mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Toxin enzyme immunoassay</intervention_name>
    <description>EIA assay: Wampole/Tech Lab Tox A/B II</description>
    <arm_group_label>Oral vancomycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nuceleic acid amplification test</intervention_name>
    <description>NAAT: Xpert C. difficile, Cepheid</description>
    <arm_group_label>Oral vancomycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stool submitted to the BJH microbiology laboratory for C. difficile testing that tests&#xD;
             negative for C. difficile toxins (C. difficile Tox A/B II, Alere, Waltham, MA) as part&#xD;
             of routine clinical care and positive by NAAT (Xpert C. difficile, Cepheid, Sunnyvale,&#xD;
             CA)&#xD;
&#xD;
          -  Clinically significant diarrhea (≥3 diarrheal bowel movements per day or ≥1 diarrheal&#xD;
             bowel movement plus abdominal pain)&#xD;
&#xD;
          -  ≥18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of a condition associated with persistent / prolonged / recurrent&#xD;
             diarrhea, including, but not limited to:&#xD;
&#xD;
          -  Upcoming chemotherapy&#xD;
&#xD;
          -  Previous or upcoming bone marrow/hematopoietic stem cell transplant,&#xD;
&#xD;
          -  Leukemia: new, not in remission, or receiving chemotherapy&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Ulcerative colitis&#xD;
&#xD;
          -  Microscopic colitis&#xD;
&#xD;
          -  Previous total colectomy&#xD;
&#xD;
          -  Previous partial colectomy without return to formed bowel movement or previous&#xD;
             resection of colon&#xD;
&#xD;
          -  Colostomy or ileostomy&#xD;
&#xD;
          -  Unable to follow study procedures&#xD;
&#xD;
          -  Not expected to survive until study follow-up is complete&#xD;
&#xD;
          -  Allergy or intolerance to oral vancomycin&#xD;
&#xD;
          -  A history of CDI in the past 3 months&#xD;
&#xD;
          -  Alternate infectious etiology for diarrhea&#xD;
&#xD;
          -  Receipt of CDI antibiotic treatment (excluding empiric treatment given while pending&#xD;
             EIA results)&#xD;
&#xD;
          -  Does not provide consent will exclude a patient from participating in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Dubberke, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <results_first_submitted>June 10, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2021</results_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03388268/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Vancomycin</title>
          <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Vancomycin</title>
          <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="37" upper_limit="81"/>
                    <measurement group_id="B2" value="64" lower_limit="48" upper_limit="77"/>
                    <measurement group_id="B3" value="65" lower_limit="37" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-white race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Receiving antibiotics at enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Detectable C. Difficile</title>
        <description>Stool specimens will be examined via culture and metagenomic analyses for the presence of detectable C. difficile. Presence will be defined as presence of culturable C. difficile in stool any time after collection of enrollment stool samples.</description>
        <time_frame>Through 8 weeks after completion of study drug</time_frame>
        <population>12 of 15 enrolled patients had follow up stool specimens available for analysis. C. difficile was detected in 9 of these 12 during the follow up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Vancomycin</title>
            <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable C. Difficile</title>
          <description>Stool specimens will be examined via culture and metagenomic analyses for the presence of detectable C. difficile. Presence will be defined as presence of culturable C. difficile in stool any time after collection of enrollment stool samples.</description>
          <population>12 of 15 enrolled patients had follow up stool specimens available for analysis. C. difficile was detected in 9 of these 12 during the follow up period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detectable Environmental Contamination</title>
        <description>Swabs from participants' home and hospital environments will be examined via culture and metagenomic analyses for the presence and/or persistence of C. difficile and other multidrug resistant organisms.</description>
        <time_frame>Through 8 weeks after completion of study drug</time_frame>
        <population>12 of 15 enrolled patients had follow up environmental swabs available for analysis. C. difficile was detected in 9 of these 12 during the follow up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Vancomycin</title>
            <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable Environmental Contamination</title>
          <description>Swabs from participants' home and hospital environments will be examined via culture and metagenomic analyses for the presence and/or persistence of C. difficile and other multidrug resistant organisms.</description>
          <population>12 of 15 enrolled patients had follow up environmental swabs available for analysis. C. difficile was detected in 9 of these 12 during the follow up period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Diarrhea in Study Participants as Defined by Daily Symptoms and Questionnaire Using the Bristol Stool Chart</title>
        <description>Duration of diarrhea will be compared between groups. Duration of diarrhea will be assessed daily during study drug using a questionnaire and the Bristol Stool Chart. The Bristol Stool Chart measures stool consistency. Diarrhea will be defined as Bristol Stool Chart types 5-7.</description>
        <time_frame>Through 8 weeks after completion of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Vancomycin</title>
            <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Diarrhea in Study Participants as Defined by Daily Symptoms and Questionnaire Using the Bristol Stool Chart</title>
          <description>Duration of diarrhea will be compared between groups. Duration of diarrhea will be assessed daily during study drug using a questionnaire and the Bristol Stool Chart. The Bristol Stool Chart measures stool consistency. Diarrhea will be defined as Bristol Stool Chart types 5-7.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="13"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Other Multidrug Resistant Organisms in the Gut Microbiome of Study Participants</title>
        <description>Stool specimens will be examined via culture and metagenomic analyses for the presence of multidrug resistant organisms before and after study drug.</description>
        <time_frame>Through 8 weeks after completion of the study drug</time_frame>
        <population>12 of 15 enrolled patients had follow up stool specimens available for analysis. Multidrug organisms were detected in 10 of these 12 during the follow up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Vancomycin</title>
            <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Other Multidrug Resistant Organisms in the Gut Microbiome of Study Participants</title>
          <description>Stool specimens will be examined via culture and metagenomic analyses for the presence of multidrug resistant organisms before and after study drug.</description>
          <population>12 of 15 enrolled patients had follow up stool specimens available for analysis. Multidrug organisms were detected in 10 of these 12 during the follow up period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through 8 weeks after completion of the study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Vancomycin</title>
          <description>125mg of oral vancomycin four times per day&#xD;
Oral Vancomycin: Oral vancomycin 125mg 4 times per day&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo four times per day&#xD;
Placebo: Sugar liquid manufactured to mimic oral vancomycin 125mg&#xD;
Toxin enzyme immunoassay: EIA assay: Wampole/Tech Lab Tox A/B II&#xD;
Nuceleic acid amplification test: NAAT: Xpert C. difficile, Cepheid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Volume overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>C. difficile EIA positive stool sample</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, vertigo, nausea/vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Syncope, altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Reske, MPH, Research Coordinator</name_or_title>
      <organization>Washington University in St. Louis</organization>
      <phone>314-747-4041</phone>
      <email>kreske@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

